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Risk Factors for Survival in a University Hospital Population of
Dogs with Epilepsy
N. Fredsø, B.C. Koch, N. Toft, and M. Berendt
Background: Although a common neurological disorder in dogs, long-term outcome of epilepsy is sparsely docu-
mented.
Objectives: To investigate risk factors for survival and duration of survival in a population of dogs with idiopathic epi-
lepsy or epilepsy associated with a known intracranial cause.
Animals: One hundred and two client owned dogs; 78 dogs with idiopathic epilepsy and 24 dogs with epilepsy associ-
ated with a known intracranial cause.
Methods: A retrospective hospital based study with follow-up. Dogs diagnosed with epilepsy between 2002 and 2008
were enrolled in the study. Owners were interviewed by telephone using a structured questionnaire addressing epilepsy sta-
tus, treatment, death/alive, and cause of death.
Results: Median life span was 7.6 years, 9.2 years, and 5.8 years for all dogs, and dogs with idiopathic epilepsy or dogs
with epilepsy associated with a known intracranial cause (P < .001), respectively. Survival time for dogs with idiopathic
epilepsy was signiﬁcantly (P = .0030) decreased for dogs euthanized because of epilepsy (median: 35 months) compared to
dogs euthanized for other reasons (median: 67.5 months). Neutered male dogs with idiopathic epilepsy had a signiﬁcant
(P = .031) shorter survival (median: 38.5 months) after index seizure compared to intact male dogs (median: 71 months).
Treatment with two antiepileptic drugs (AED0s) did not negatively inﬂuence survival (P = .056).
Conclusion and Clinical Importance: Dogs with idiopathic epilepsy can in many cases expect a life span close to what is
reported for dogs in general. In dogs where mono-therapy is not suﬃcient, the need for treatment with two AED0s is not
linked to a poor prognosis.
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Epilepsy in dogs and people have been associatedwith an increased risk of premature death1–4 and
might in dogs lead to euthanasia3,5–7 if seizure
control is insuﬃcient. Survival studies on epilepsy in
dogs including both idiopathic and symptomatic cases
have reported a median life span of 7.0 years.2,3
Many factors might inﬂuence survival. Acute self-
sustaining seizures (status epilepticus) can be a direct
cause of death. Furthermore, dogs experiencing sta-
tus epilepticus or cluster seizures have a signiﬁcantly
decreased survival time compared to dogs not suﬀer-
ing from such phenomenon.5–9 Age at epilepsy debut
aﬀects survival in Border collies and Australian shep-
herds, where a signiﬁcantly decreased survival time is
associated with an onset of seizures before the age
of 2 years.8,9 Other studies, including both pure
breeds and cross-breeds, have however not shown
any correlation between age at seizure onset and
survival.3,6
Sudden unexpected death in epilepsy (SUDEP)
might occur in individuals with epilepsy. SUDEP is
well recognized in humans10 with sudden death being
24 times more likely in people with epilepsy than in
the general population.11 Although sparsely investi-
gated, there are indications that SUDEP also occur in
dogs.3,6,12
Although a condition which implicate a possible risk
of premature death, epilepsy is also a potentially self-
limiting disorder and remission might occur either
spontaneously or upon treatment.13 Remission of epi-
lepsy has been documented in several studies of dogs
ranging between 14 and 24% of the populations inves-
tigated.3,6,8,9,12,14
Only few studies have provided information on
mortality in populations of dogs, including purebreds
and crossbreds, with idiopathic and symptomatic epi-
lepsy. The aim of this study was to investigate sur-
vival and prognosis in such a population and to
investigate selected risk factors possibly inﬂuencing
survival time.
Materials and Methods
Study Design and Study Population
The study was designed as a retrospective hospital based study
with follow-up. The study population consisted of dogs diag-
nosed with idiopathic epilepsy or epilepsy associated with a
known intracranial cause between 2002 and 2008 at the Small
Animal Veterinary Teaching Hospital, University of Copenhagen.
To be included in the study, the dogs should have a diagnosis of
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idiopathic epilepsy or epilepsy associated with a known intracra-
nial cause from the hospital neurology clinic.
Definitions Applied in the Study
Epilepsy was deﬁned in this study as recurrent seizures (two or
more) of intracranial origin. To qualify for a diagnosis of
idiopathic epilepsy, dogs had a normal interictal clinical and neu-
rological examination and a complete blood count and biochem-
istry proﬁle within reference range. Furthermore, a minimum
follow-up of 3 years after diagnosis, if the dog was still alive at
the time of follow-up, or until death, with no indication of pro-
gressive intracranial disease was available. This implies that the
dogs could have died in the time between diagnosis and follow-
up. Diagnostic imaging was desirable. A diagnosis of epilepsy
associated with a known intracranial cause required that a intra-
cranial lesion was conﬁrmed by computer tomography (CT),
magnetic resonance imaging (MRI), cerebrospinal ﬂuid (CSF)
analysis, or post mortem histopathology.
Seizures were classiﬁed as primary generalized or focal with or
without secondary generalization.
Cluster seizures were deﬁned as >1 epileptic seizure within
24 hours. Status epilepticus was deﬁned as “a single epileptic sei-
zure event lasting more than 30 minutes or a series of seizures dur-
ing which the normal level of brain function was not regained
between ictal events in a period longer than 30 minutes.”15 SUDEP
was deﬁned as “sudden, unexpected, witnessed or unwitnessed,
nontraumatic and nondrowning death, with or without evidence of
a seizure and excluding documented status epilepticus.” 4 Epilepsy-
related cause of death was deﬁned as euthanasia motivated by cir-
cumstances directly associated with the epileptic condition. In cases
where the epileptic condition was only one of more factors contrib-
uting to the decision of euthanasia death was registered as due to
other causes. Dogs were registered as receiving antiepileptic treat-
ment if they received treatment with a single drug (mono-therapy)
or a combination of two or more antiepileptic drugs (AED0s).
Remission of epilepsy was deﬁned as spontaneous remission (no
seizure for ≥3 years without antiepileptic treatment) or remission
upon treatment (no seizure for ≥3 years while receiving antiepilep-
tic treatment).3,12 Both deﬁnitions of remission implied seizure
freedom at the time of follow-up or at time of death.
Life span investigated time from date of birth and until time of
death/time of follow-up and survival time investigated time from
date of index seizure and until time of death/time of follow-up.
Telephone Follow-up
A follow-up investigation was conducted in January and Feb-
ruary 2012. Owners of included dogs were contacted by tele-
phone and interviewed using a structured questionnaire. The
questionnaire consisted of three sections:
Section 1 conﬁrmed the ID of the dog and investigated the
status (dead or alive) of the dog.
Section 2 investigated the cause of death in deceased dogs
and whether death had occurred spontaneously or the dog
had been euthanized. In the case of euthanasia, owners were
asked which factors had inﬂuenced the decision.
Section 3 investigated seizure history including date of index
seizure, seizure semiology, information on antiepileptic
treatment and seizure control, occurrence of status epilepti-
cus, cluster seizures, or both and ﬁnally possible remission.
To identify possible recall bias, a comparison of the date of index
seizure stated in the dogs’ medical record was made with the date
of index seizure stated by the owners in the follow-up interview.
To secure a standardized interview, one investigator (BCK) per-
formed all the interviews.
Statistical Analysis
The study population was characterized by tabulating clinical
variables stratiﬁed by epilepsy status. Data included information
on sex, neutering status, breed, age at index seizure, seizure type,
status epilepticus, cluster seizures, antiepileptic treatment, and
remission of epilepsy. Median life span and median survival time
for dogs with epilepsy (idiopathic or associated with a known
intracranial cause) were estimated using Kaplan–Meier survival
analysis.16 Dogs alive at the time of follow-up were censored.
Furthermore, Kaplan–Meier was used to estimate median life
span and survival time in dogs with idiopathic epilepsy stratiﬁed
by sex, neutering status, age at index seizure (≤24 months,
>24 months), seizure type, treatment, and cause of death. Sur-
vival curves of the diﬀerent strata were compared using a log-
rank test. Multivariable analysis of the above risk factors was
carried out using Cox proportional hazard models.16 The analysis
was carried out as a backward elimination procedure, where all
variables where included and removed variables were reinserted
one at a time in the ﬁnal model.
All analyses were carried out using the survival package in R
version 2.14.2.17 By using chi-squared test and Fisher’s exact test,
the association between occurrence of cluster seizures and status
epilepticus and the cause of death and neutering status (male
dogs), respectively, was investigated. Statistical signiﬁcance was
deﬁned as P ≤ .05 in all analyses.
Results
Descriptive Analysis
Total Population. One hundred and thirty-one dogs
met the inclusion criteria of the study. Twenty-eight
dogs were lost to follow-up as the owners could not be
reached and one owner declined to participate in the
study. Thus, 102 dogs constituted the ﬁnal study popu-
lation, 78 dogs with idiopathic epilepsy and 24 dogs
with epilepsy associated with a known intracranial
cause (Table 1).
Of the 102 dog owners who participated in the
investigation, 84 (82%) were able to recall the time of
their dog0s index seizure with a high accuracy (weeks
proximity) at follow-up when comparing to the date
stated in the dog0s medical record at the ﬁrst clinical
consult at the hospital.
Dogs with Idiopathic Epilepsy. The group of dogs
with idiopathic epilepsy consisted of 67 purebreds (dis-
tributed among 42 breeds) and 11 crossbreeds. Of
these, 16 were females (8 intact, 8 neutered) and 62
were males (38 intact, 24 neutered). The median age
at index seizure was 25 months (Q1–Q3: 12.25–
50.75 months, range: 3–87 months), 2.1 years. The
median number of months, the dogs had epilepsy
(from index seizure to time of either death or follow-
up) was 61 months (range: 2–166 months). Three dogs
had epilepsy for less than 10 months when they were
euthanized. All three dogs had normal hematology
and biochemistry proﬁles. Further testing in the three
dogs, which did not reveal any abnormalities, was
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thyroid status and cardiac ultrasound (one dog), CSF
examination (one dog) and dynamic bile acid testing,
ACTH stimulation test and radiographs of the thorax
and abdomen (one dog).
Fifteen dogs (19%) experienced focal seizures
whereas 49 dogs (63%) experienced focal seizures with
secondary generalization and 11 dogs (14%) experi-
enced primary generalized seizures. Seizure type could
not be classiﬁed in 3 dogs (4%). A history of cluster
seizures was reported in 47 dogs (60%) and 14 dogs
(18%) experienced status epilepticus (Table 1). In four
of these dogs, status epilepticus occurred more than
once. MRI was performed in 14 dogs, CT was per-
formed in 16 dogs and 9 dogs had a CSF examination
(6/9 dogs had also MRI performed and 2/9 had CT
performed). No abnormalities were found on any of
these specialized diagnostic tests.
At the time of follow-up or time of death, 41 dogs
(53%) received mono-therapy with phenobarbital and
28 dogs (36%) received treatment with a combination
of phenobarbital and potassium bromide. One dog
(1%) received treatment with phenobarbital, potassium
bromide, and levetiracetam. Eight dogs did not receive
any antiepileptic treatment. Ten dogs (13%) met the
criteria of remission of which 4 dogs had entered
spontaneous remission while 6 dogs had entered remis-
sion upon treatment (5 mono-therapy and 1 a combi-
nation of two AED0s) (Table 1). Of the 10 dogs, 3
dogs had a history of cluster seizures.
Dogs with Epilepsy Associated with a Known Intra-
cranial Cause. The group of dogs with epilepsy associ-
ated with a known intracranial cause consisted of 22
purebreds (distributed among 19 breeds) and 2 cross-
breeds. Of these, 4 were females (3 intact, 1 neutered)
and 20 were males (15 intact, 5 neutered). Eleven dogs
(46%) were diagnosed with intracranial neoplasia, nine
dogs (38%) with intracranial inﬂammatory disease,
three dogs (12%) with malformation (hydrocephalus)
and one dog (4%) with hemorrhagic stroke. Upon pre-
sentation 6/24 dogs had a normal interictal neurologi-
cal examination including a normal interictal behavior
reported by the owner. Median age at index seizure
was 47.5 months (Q1–Q3: 14.75–75.25 months, range:
1–138 months), 4 years. The median number of
months the dogs had epilepsy (from index seizure to
time of either death or follow-up) was 8 months
(range: 1–73 months).
Seven dogs (29%) experienced focal seizures while
17 dogs (71%) experienced focal seizures with second-
ary generalization. A history of cluster seizures was
Table 1. Characterization of the study population including dogs with idiopathic epilepsy and epilepsy associated
with a known intracranial cause.
Idiopathic Epilepsy
Epilepsy Associated with a
Known Intracranial Cause
n % n %
Overall (total population of 102 dogs) 78 76 24 24
Alive at follow-up 20 26 1 4
Dead at follow-up 58 74 23 96
Sex and neutering status
Male 62 79 20 83
Intact 38 61 15 75
Neutered 24 39 5 25
Female 16 21 4 17
Intact 8 50 3 75
Neutered 8 50 1 25
Seizure type
Focal 15 19 7 29
Focal with secondary generalization 49 63 17 71
Primary generalized 11 14 0 0
Unclassiﬁed 3 4 0 0
Antiepileptic treatment 70 90 17 71
Monotherapy 41 59 14 82
Two antiepileptic drugs 28 40 3 18
More than two drugs 1 1 0 0
Acute seizures 61 78 24 100
Cluster seizures 47 77 18 75
Status epilepticus 14 23 6 25
Remission 10 13
Spontaneously 4 40 0 0
Upon treatment 6 60 0 0
Death/Euthanasia 58 74 23 96
Motivated by epilepsy 30 52 19a 83
Other causes 28 48 4 17
a6/19 dogs were euthanized because of a grave prognosis caused by the primary intracranial pathology.
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reported in 18 (75%) dogs and 6 dogs (25%) had
experienced status epilepticus (Table 1). Seventeen
dogs (7 with inﬂammatory disease, 8 with intracranial
tumor, 1 with malformation, and 1 with hemorrhagic
stroke) received treatment with AED0s. Treatment was
either mono-therapy with phenobarbital or with a
combination of phenobarbital and potassium bromide.
None of the dogs achieved remission.
Survival Analysis
Total Population. Twenty-one of the 102 dogs that
participated in the study were alive at the time of fol-
low-up while 81 dogs were deceased. A median life
span of 91 months (95% CI: 83–119), 7.6 years, was
estimated for the total study population (including
both idiopathic cases and cases with epilepsy associ-
ated with a known intracranial cause) with a median
survival time from index seizure being 56 months
(95% CI: 37–67), 4.7 years.
Dogs with Idiopathic Epilepsy. At the time of follow-
up 20 (26%) dogs were alive while 58 (74%) dogs were
dead. A median life span of 110 months (95% CI: 88–
123), 9.2 years, was estimated with a median survival
time after index seizure being 66 months (95% CI: 60–
81), 5.5 years (Table 2).
A signiﬁcant association was found between survival
time and neutering status for male dogs with neutered
male dogs having a signiﬁcantly (P = .031) shorter sur-
vival time (median: 38.5 months) than intact male dogs
(median: 71 months). Furthermore, an association was
shown between neutering status of male dogs and the
occurrence of cluster seizures with neutered male dogs
experiencing signiﬁcant (P = .029, using Fisher0s exact
test) more cluster seizures compared to intact male
dogs. There was a strong signiﬁcant eﬀect of cluster
seizures (P < .001) and status epilepticus (P < .001) on
the survival time. No signiﬁcant association was found
in survival time when stratiﬁed by sex (P = .61), neu-
tering status for females (P = .45), age at index seizure
(P = .32), seizure type (P = .067), or between dogs
receiving antiepileptic treatment, or no treatment
(P = .67). Nor did testing mono-therapy against a
combination of two AED0s reveal any signiﬁcant dif-
ference (P = .056). When the above variables were
analyzed in a multivariable model using Cox propor-
tional hazards for the survival time after seizure onset,
only cluster seizures (P = .0027) and status epilepticus
(P = .0098) remained in the model. Hazard ratio for
cluster seizures and status epilepticus were 9.3 (95%
CI; 2.2–40.0) and 2.7 (95% CI; 1.3–5.6) respectively.
The dog that received phenobarbital, potassium bro-
mide, and levetiracetam was excluded from calcula-
tion.
Epilepsy-related cause of euthanasia was reported in
30/58 dogs (52%). One dog (a male) died spontane-
ously after a generalized tonic-clonic seizure, which did
not diﬀer from previous seizures in the dog (possible
SUDEP). The dog, an Old English sheepdog, experi-
enced cluster seizures regularly, and the owner
reported a poor response to antiepileptic treatment
with seizure episodes every other week. The median
life span for dogs euthanized because of epilepsy-
related causes were 71 months (Q1–Q3: 40.75–104.5)
while the median survival time was 35 months (Q1–
Q3: 18.75–63.25).
A signiﬁcant association was found between cause
of death, life span (P = .00021), and survival time
(P = .0030) (Figs 1, 2). Dogs that died/were euthanized
because of causes directly related to the epileptic con-
dition had a signiﬁcant shorter median life span and
median survival time compared to dogs that died or
were euthanized because of other causes. An associa-
tion was also demonstrated between cause of death,
the occurrence of cluster seizures, or both status epi-
lepticus. The frequency of cluster seizures (P < .001)
and status epilepticus (P = .003) were signiﬁcantly
increased in dogs in which epilepsy was the direct
cause of euthanasia compared to dogs in which death
was motivated by other causes.
Dogs with Epilepsy Associated with a Known
Intracranial Cause. At the time of follow-up one dog
(4%) was alive while 23 dogs (96%) were dead. The
median life span was 69.5 months (95% CI: 56–83),
5.8 years, whereas the median survival time after index
seizure was 8 months (95% CI: 3–21), 0.7 years
(Table 2). Epilepsy-related cause of euthanasia was
reported in 19/23 dogs (83%). A signiﬁcant association
was found between survival time and the underlying
etiology, with dogs diagnosed with inﬂammatory CNS
disease having a signiﬁcantly longer survival time
(P = .0096) than dogs diagnosed with intracranial neo-
plasia, malformation, or hemorrhagic stroke (Fig 3).
Comparison of the Two Groups. When comparing
median survival time for the two strata idiopathic epi-
lepsy and epilepsy associated with a known intracra-
nial cause, dogs with idiopathic epilepsy had a
signiﬁcant (P < .001) longer survival time than dogs
Table 2. Age at index seizure, time with epilepsy, life span, and survival time for the study population.
n
Age at Index Seizure (Months),
Median (25–75%)
Life Span (Months),
Median (95% CI)
Survival Time (Months),
Median (95% CI)
Idiopathic epilepsy 78 25 (12.25–50.75) 110 (88–123) 66 (60–81)
Epilepsy associated with
a known intracranial cause
24 47 (14.75–75.25) 69.5 (56–83) 8 (3–21)
Cause of death
Motivated by epilepsy 30 16 (10.08–37.75) 71 (52–91) 35 (28–61)a
aAs all dogs were dead, the median survival time represent the true median and not the estimated.
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with epilepsy associated with a known intracranial
cause (Fig 4).
Discussion
This study shows that in many cases dogs with idio-
pathic epilepsy can expect a life span close to what is
reported for dogs in general. The few studies which
have investigated survival in populations of dogs con-
sisting of both purebred and crossbreed dogs have esti-
mated a median life span of 7.0 years when including
both idiopathic and symptomatic cases.2,3 This is in
accordance with the median life span of 7.6 years
found for the total study population in this study.
When investigating survival according to etiology,
however, our study interestingly showed that dogs with
idiopathic epilepsy had a median life span close to the
median life span of 10.0 years reported for dogs in
general.2 This information is of interest for clinicians
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Fig 1. Kaplan–Meier plot of survival time for dogs with idio-
pathic epilepsy stratiﬁed by cause of death. Solid line = Death
motivated by the epileptic condition (n = 30). Dashed line =
Death because of other causes (n = 28).
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Fig 2. Kaplan–Meier plot of life span for dogs with idiopathic
epilepsy stratiﬁed by cause of death. Solid line = Death moti-
vated by the epileptic condition (n = 30). Dashed line = Death
because of other causes (n = 28).
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Fig 3. Kaplan–Meier plot of survival for dogs with epilepsy
associated with a known intracranial cause stratiﬁed by intracra-
nial etiology. Dashed line = inﬂammatory disease (n = 9), Solid
line = neoplastic disease (n = 11), Dotted line = malformation
(n = 3), and Dot-dash line = hemorrhagic stroke (n = 1). Hash
mark indicates censored data.
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Fig 4. Kaplan–Meier plot of survival time in dogs with idio-
pathic epilepsy and epilepsy associated with a known intracranial
cause. Solid line = dogs with idiopathic epilepsy (n = 78). Dashed
line = dogs with epilepsy associated with a known intracranial
cause (n = 24). Hash marks indicate censored data.
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when discussing prognosis of idiopathic epilepsy with
dog owners.
The study conﬁrmed that dogs with epilepsy associ-
ated with a known intracranial cause have an
increased risk of premature death when compared to
dogs with idiopathic epilepsy. This result is not unex-
pected but is, however, of interest as no previous stud-
ies have provided statistical evidence for the
association between intracranial lesions causing symp-
tomatic epilepsy and a decreased survival time.
Our ﬁnding is consistent with human epilepsy stud-
ies on survival, which have documented that case fatal-
ity is highest in individuals with epilepsy associated
with a known intracranial cause compared to idio-
pathic epilepsy.1,4 A similar result, which found a sig-
niﬁcantly longer mean survival time in dogs with
idiopathic epilepsy compared to dogs with epilepsy
associated with a known intracranial cause, has previ-
ously been reported.6 However, the study only
included dogs with seizure onset before the age of
1 year, and the results are therefore not directly com-
parable to this study.
Conﬂicting results exist in human medicine with
regard to the question of premature death associated
with idiopathic epilepsy. Some studies have reported a
slightly increased mortality while others have found no
increased risk compared to the general popula-
tion.1,4,18,19
In this study, dogs with symptomatic epilepsy
caused by inﬂammatory disease had a signiﬁcantly
longer survival time compared to dogs with epilepsy
caused by neoplasia, malformation, or hemorrhagic
stroke. This ﬁnding might reﬂect that anti-inﬂamma-
tory treatment options are available.
When investigating risk factors for idiopathic epi-
lepsy neutered male dogs had a signiﬁcantly shorter
survival time when compared to intact males. The fact
that a signiﬁcantly higher proportion of neutered male
dogs experienced cluster seizures compared to intact
males might explain this ﬁnding. Whether testosterone
possesses pro- or anticonvulsive properties is an ongo-
ing subject of investigation.20–23 A seizure protective
eﬀect, through modulation of the GABA receptor dri-
ven by testosterone-derived neurosteroid 3a-andro-
stanediol, has however been suggested in some in vivo
rodent studies.20,21
Although tempting to assume that treatment with a
combination of two AED0s reﬂects more grave (diﬃ-
cult to control) epilepsy, an interesting ﬁnding of our
study was, that dogs receiving a combination of two
AED0s did not diﬀer signiﬁcantly from dogs receiving
mono-therapy with respect to survival. A similar result
was reported in Australian shepherds with idiopathic
epilepsy whose survival was also not inﬂuenced by
poly-therapy.9
Death/euthanasia was directly motivated by epilepsy
in 52% of the dogs with idiopathic epilepsy, of which
a signiﬁcant proportion had a history of cluster sei-
zures, status epilepticus or both. Both cluster seizures
and status epilepticus have previously been reported as
risk factors of survival in epileptic dogs.3,5–7 Neither
cluster seizures or status epilepticus are well tolerated
from an owners perspective3,24 which underlines that
prompt treatment and continuous optimizing of seizure
control is of a central point of attention for the clini-
cian.
Genetic factors might inﬂuence the severity of epi-
lepsy in certain breeds with idiopathic epilepsy and
thus inﬂuence survival.8,9,12,25 The median survival
time (time from index seizure to death/follow-up) for
dogs with idiopathic epilepsy reported in this study is
comparable to the median survival time of 4.25 years
reported in Belgian shepherds12 experiencing a rela-
tively mild form of focal idiopathic genetic epilepsy. A
graver prognosis has been found in Border collies in
which the median survival time was only 2.07 years.8
The fact that certain breeds might experience epilepsy
subtypes, which are diﬃcult to control, is important to
discuss with owners bringing such pure breed epileptic
dogs to the clinic.
One case of possible SUDEP occurred in a male
dog with idiopathic epilepsy after an episode of a sin-
gle generalized tonic-clonic seizure. The dog experi-
enced a poor response to AED0s with episodes of
cluster seizures regularly and seizures every other
week. In human epileptology, SUDEP is a well-known
phenomenon with young age, male gender, poor sei-
zure control and episodes with generalized tonic-clonic
seizures being risk factors.10 SUDEP has previously
been reported to occur in dogs3,6,12 and remains an
area for further investigation.
This study documented a remission of epilepsy of
13% and thus conﬁrmed that idiopathic epilepsy in
dogs is not necessarily a chronic condition. Our result
is supported by a previous study in using an identical
deﬁnition for remission, and which found a remission
rate of 15%.3 Three of the dogs that entered remission
in this study had a history of one or more episodes of
cluster seizures, indicating that remission can be
achieved even in such severe cases. This has also been
reported for Border collies and Australian shepherds
diagnosed with idiopathic epilepsy.8,9
Although desirable from a diagnostic perspective,
some owners declined neuroimaging and imaging
results were therefore not available for a proportion of
dogs with idiopathic epilepsy. This is a weakness to
the study as cases with an intracranial lesion might fal-
sely have been included in the idiopathic epilepsy
group. However, none of these dogs revealed interictal
signs of intracranial lesions at inclusion, and neither
did they develop such progressive signs until death or
follow-up after a minimum of 3 years, which support
the diagnosis of idiopathic epilepsy. For the three dogs
with a follow-up period less than 10 months, no inte-
rictal neurological signs or behavioral changes were
observed. This supports a diagnosis of idiopathic epi-
lepsy although there is a possibility that this is not the
case.
The fact that no abnormalities were detected in the
30 dogs with a CT- or MRI-scan or in the 9 dogs that
had a CSF examination also supports the validity of
our case deﬁnition. It has previously been reported
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that only 2.2% of dogs under the age of six with a
normal neurological examination had signiﬁcant intra-
cranial abnormalities on MRI.26 However, this result
cannot be directly applied to the group of dogs with
idiopathic epilepsy in this study, as inclusion criteria in
the two studies are not identical.
A possible limitation when working with question-
naires and collecting historical information from own-
ers is recalling bias. Yet, 82% of the owners in this
study were able to state almost the exact date of the
index seizure of their dogs compared with what was
recorded in the dogs’ medical record at their ﬁrst hos-
pital visit. This indicates that recall bias only played a
minor role in this study.
Conclusion
Our study conﬁrmed that dogs with epilepsy associ-
ated with a known intracranial cause have a grave prog-
nosis, which is associated with the nature of the primary
intracranial lesion. This study shows that dogs with idi-
opathic epilepsy in many cases can expect a median life
span close to what is reported for dogs in general.
Another encouraging ﬁnding was that receiving treat-
ment with a combination of two AED0s did not aﬀect
survival negatively. However it is important, when
advising owners, to include the information that certain
breeds express epilepsy phenotypes that might be diﬃ-
cult to manage and that in each single patient, individ-
ual factors and decisions made by the clinician and the
owner together will inﬂuence prognosis and survival.
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